AxoGen, Inc. (AXGN)


-0.11 (-2.24%)
Symbol AXGN
Price $4.8
Beta 0.675
Volume Avg. 0.31M
Market Cap 206.321M
Shares () -
52 Week Range 4.63-13.66
1y Target Est -
DCF Unlevered AXGN DCF ->
DCF Levered AXGN LDCF ->
ROE -22.32% Sell
ROA -11.56% Sell
Operating Margin -
Debt / Equity 69.30% Buy
P/E -8.89 Strong Sell
P/B 2.12 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest AXGN news

Ms. Karen Zaderej
Medical Devices
NASDAQ Capital Market

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.